TK-6302 / T-knife Therap - LARVOL DELTA

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy (GlobeNewswire) - "T-knife Therapeutics...announced multiple data presentations at the American Association for Cancer Research (AACR) Annual Meeting. Preclinical data demonstrated that TK-6302, T-knife’s supercharged PRAME targeting TCR-T, outperformed other clinical-stage approaches. The company plans to submit a Clinical Trial Application (CTA) for TK-6302 in the fall of 2025 and to initiate a Phase 1 clinical study of TK-6302 in early 2026....detailed data showing best-in-class potential for TK-6302. Through the incorporation of a high-affinity TCR, a chimeric CD8 co-receptor that engages CD4 T cells and provides co-stimulation upon TCR engagement, and a FAS checkpoint converter that boosts T cell fitness in the periphery and prevents apoptosis in the tumor, TK-6302 demonstrated higher in vitro anti-tumor activity compared to known clinical-stage PRAME TCR-T approaches."

New P1 trial • Preclinical • Oncology

TK-6302, a supercharged PRAME TCR-T cell therapy containing a high affinity TCR, an activating CD8 coreceptor (costimCD8 CoR) and a Fas-based switch receptor, drives sustained anti-tumor responses (AACR 2025) - "Supercharged PRAME TCR-T therapy demonstrates best-in-class preclinical anti-tumor efficacy and T cell fitness compared to current clinical stage PRAME TCR-T approaches, providing the potential for deep and durable responses in hard-to-treat indications."

IO biomarker • Melanoma • Oncology • Sarcoma • Solid Tumor • CD40 • CD8 • FAS • FASLG • PRAME

T-knife Therapeutics Announces Five Presentations at American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "T-knife Therapeutics...announced that five abstracts highlighting its PRAME-targeted TCR-T therapy, TK-6302, and its platform technologies will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting....Multiple presentations demonstrate that T-knife’s proprietary next-generation technologies address important challenges with current cell therapy constructs, including boosting T cell fitness and persistence within an immunosuppressive tumor microenvironment. TK-6302, a supercharged PRAME T cell therapy, is rapidly advancing towards a Clinical Trial Application (CTA) filing in the fourth quarter of 2025."

New trial • Preclinical • Solid Tumor